These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30592773)

  • 41. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.
    Heslin MJ; Yan J; Weiss H; Shao L; Owens J; Lucas VS; Diasio RB
    Cancer Chemother Pharmacol; 2003 Nov; 52(5):399-404. PubMed ID: 12904894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans.
    Khor SP; Amyx H; Davis ST; Nelson D; Baccanari DP; Spector T
    Cancer Chemother Pharmacol; 1997; 39(3):233-8. PubMed ID: 8996526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
    Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
    Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalized Chronomodulated 5-Fluorouracil Treatment: A Physiologically-Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy.
    Marok FZ; Wojtyniak JG; Selzer D; Dallmann R; Swen JJ; Guchelaar HJ; Schwab M; Lehr T
    Clin Pharmacol Ther; 2024 Jun; 115(6):1282-1292. PubMed ID: 38264789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
    Maillard M; Launay M; Royer B; Guitton J; Gautier-Veyret E; Broutin S; Tron C; Le Louedec F; Ciccolini J; Richard D; Alarcan H; Haufroid V; Tafzi N; Schmitt A; Etienne-Grimaldi MC; Narjoz C; Thomas F;
    Br J Clin Pharmacol; 2023 Feb; 89(2):762-772. PubMed ID: 36104927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers.
    Henricks LM; Jacobs BAW; Meulendijks D; Pluim D; van den Broek D; de Vries N; Rosing H; Beijnen JH; Huitema ADR; Guchelaar HJ; Cats A; Schellens JHM
    Br J Clin Pharmacol; 2018 Dec; 84(12):2761-2769. PubMed ID: 30047584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.
    Nagata M; Hidaka Y; Hatakeyama K; Kawano Y; Iwakiri T; Okumura M; Arimori K
    Biopharm Drug Dispos; 2011 Mar; 32(2):126-30. PubMed ID: 21341281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
    Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
    J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients.
    Kristensen MH; Pedersen P; Mejer J
    J Int Med Res; 2010; 38(4):1313-23. PubMed ID: 20926004
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
    Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
    Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Automatic quantification of uracil and dihydrouracil in plasma.
    Robin T; Saint-Marcoux F; Toinon D; Tafzi N; Marquet P; El Balkhi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Apr; 1142():122038. PubMed ID: 32169798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
    Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Saif MW; Hashmi S; Bell D; Diasio RB
    Expert Opin Drug Saf; 2009 Sep; 8(5):507-14. PubMed ID: 19663627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
    Jiang H; Lu J; Jiang J; Hu P
    J Clin Pharmacol; 2004 Nov; 44(11):1260-72. PubMed ID: 15496644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
    Ciccolini J; Mercier C; Dahan L; Evrard A; Boyer JC; Richard K; Dales JP; Durand A; Milano G; Seitz JF; Lacarelle B
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):272-5. PubMed ID: 16292536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry.
    Jiang H; Jiang J; Hu P; Hu Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Mar; 769(1):169-76. PubMed ID: 11936689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
    Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
    Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889.
    Bellibas SE; Patel I; Chamorey E; Brivet B; Bush ED; Kircher C; Nave S; Banken L; Renée N; Milano G
    Clin Cancer Res; 2004 Apr; 10(7):2327-35. PubMed ID: 15073108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.